
    
      A phase II study of radiation with concomitant and then sequential Temozolomide in patients
      with newly diagnosed supratentorial malignant glioma who have undergone surgery with Gliadel
      wafer insertion. To determine the safety and efficacy of Gliadel 3.85% wafers plus surgery
      and limited field radiation therapy with concomitant Temozolomide followed by Temozolomide
      alone in patients undergoing initial surgery for newly diagnosed unifocal moderate to high
      grade glioma.
    
  